Use of bisphosphonates (Bis) combined with sunitinib (Su) to improve the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC)

被引：0
|
作者：
Peer, Avivit
Ish-Shalom, Maya
Hammers, Hans J.
Eisenberger, Mario A.
Sinibaldi, Victoria J.
Pili, Roberto
Maimon, Natalie
Gottfried, Maya
Hayat, Henry
Kovel, Svetlana
Sella, Avishay
Neumann, Avivit
Boursi, Ben
Berger, Raanan
Carducci, Michael Anthony
Keizman, Daniel
机构：
[1] Rambam Hlth Care Campus, Haifa, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Meir Med Ctr, Genitourinary Oncol Serv,Div Oncol, Kefar Sava, Israel
[3] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[5] Wolfson Med Ctr, Dept Oncol, Holon, Israel
[6] Asaf Harofe Med Ctr, Dept Oncol, Zerifin, Israel
[7] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel
[8] Rambam Med Ctr, Dept Oncol, Haifa, Israel
[9] Chaim Sheba Med Ctr, Ramat Gan, Israel
[10] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
[11] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[12] Sidney Kimmel Comprehens Canc, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4619
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Use of HE4 and CA125 to predict surgical outcome and for prognostic value for progression-free survival (PFS) and overall survival (OS) in primary epithelial ovarian cancer (EOC) patients (pts)
    Braicu, Ioana
    Chekerov, Radoslav
    Richter, Rolf
    Vergote, Ignace B.
    Mahner, Sven
    Zeimet, Alain G.
    Ganapathi, Ram N.
    Woelber, Linn Lena
    Castillo-Tong, Dan Cacsire
    Cadron, Isabelle
    Zeillinger, Robert
    Fotopoulou, Christina
    Sehouli, Jalid
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] PROGRESSION-FREE AND OVERALL SURVIVAL OF PATIENTS TREATED WITH PRESURGICAL SUNITINIB PRIOR TO CYTOREDUCTIVE NEPHRECTOMY (CN) IN CLEAR CELL SYNCHRONOUS METASTATIC RENAL CELL CARCINOMA (MRCC)
    Bex, Axel
    Blank, Christian
    Chowdhury, Simon
    Nichol, David
    Peters, John
    Horenblas, Simon
    O'Brien, Tim
    Sarwar, Naveed
    Haanen, John
    Powles, Thomas
    JOURNAL OF UROLOGY, 2011, 185 (04): : E709 - E710
  • [33] Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
    Patil, S.
    Figlin, R. A.
    Hutson, T. E.
    Michaelson, M. D.
    Negrier, S.
    Kim, S. T.
    Huang, X.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2011, 22 (02) : 295 - 300
  • [34] The relationship between overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in immune checkpoint inhibitor clinical trials of head and neck squamous cell carcinoma (HNSCC): A systematic review and meta-analysis
    Wang, X.
    Ballas, M.
    Chen, H.
    Bell, K. F.
    Slowley, A.
    Ellis, C.
    Baccan, C.
    Turner, D. C.
    Zhou, H.
    ANNALS OF ONCOLOGY, 2020, 31 : S675 - S676
  • [35] Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α)
    Cella, D.
    Li, J. Z.
    Cappelleri, J. C.
    Bushmakin, A.
    Charbonneau, C.
    Kim, S. T.
    Chen, I.
    Michaelson, M. D.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC)
    Brown, J. E.
    Lipton, A.
    Cook, R. J.
    Michaelson, D.
    Coleman, R. E.
    Saad, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib
    Vanmechelen, Maxime
    Lambrechts, Diether
    Van Brussel, Thomas
    Verbiest, Annelies
    Couchy, Gabrielle
    Schoffski, Patrick
    Dumez, Herlinde
    Debruyne, Philip R.
    Lerut, Evelyne
    Machiels, Jean-Pascal
    Richard, Vincent
    Albersen, Maarten
    Verschaeve, Vincent
    Oudard, Stephane
    Mejean, Arnaud
    Wolter, Pascal
    Zucman-Rossi, Jessica
    Beuselinck, Benoit
    CLINICAL GENITOURINARY CANCER, 2019, 17 (02) : E235 - E246
  • [38] ZOLEDRONIC ACID (ZOL) REDUCES THE INCIDENCE OF SKELETAL-RELATED EVENT (SRES) AND MAY IMPROVE SURVIVAL IN PATIENTS WITH BONE METASTASES (METS) FROM RENAL CELL CARCINOMA (RCC): A RETROSPECTIVE INTEGRATED ANALYSIS
    Michaelson, D.
    Kpamegan, E. E.
    Perez, J. Ricardo
    Brown, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 287 - 287
  • [39] Superior overall survival (OS), progression-free survival (PFS), and clinical response (CR) predictions for patients with non-small cell lung cancer (NSCLC) using Cellworks Singula: myCare-022-05.
    Velcheti, Vamsidhar
    Castro, Michael
    Watson, Drew
    Kapoor, Shweta
    Tyagi, Anuj
    Sauban, Mohammed
    Alam, Aftab
    Roy, Kunal Ghosh
    Rajagopalan, Swaminathan
    Kulkarni, Shruthi
    Mundkur, Nirjhar
    Christie, Jim
    Suseela, Rakhi Purushothaman
    Ghosh, Adity
    Basu, Kabya
    Sahu, Diwyanshu
    Ullal, Yashaswini
    Nair, Prashant
    Ahluwalia, Manmeet Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Association of percentage of tumor burden removed with debulking nephrectomy and progression-free survival (PFS) in metastatic renal cell carcinoma (mRCC) patients (Pts) treated with VEGF-targeted therapy
    Barbastefano, J.
    Garcia, J. A.
    Elson, P.
    Wood, L. S.
    Lane, B. S.
    Dreicer, R.
    Campbell, S.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345